Medication and Pregnancy: What to Consider

The question of what to do about psychiatric medication during pregnancy is one of the most anxiety-provoking decisions many people face — and one of the most frequently made without adequate information on both sides of the risk.

Two things are both true at once: some psychiatric medications carry risks in pregnancy that need to be understood. And untreated psychiatric illness during pregnancy also carries real risks that are too often minimized in conversations that focus primarily on medication.

The Risks of Untreated Psychiatric Illness During Pregnancy

The default assumption in many conversations about medication in pregnancy is that stopping medication is the safer choice. This assumption is often incomplete.

Significant depression or anxiety during pregnancy can affect nutrition, sleep, prenatal care engagement, and stress physiology in ways that have documented consequences for pregnancy outcomes. ACOG notes that depression during pregnancy has been linked to babies being born early or too small, and that untreated depression raises the risk of postpartum depression. Severe psychiatric illness — including major depressive disorder with significant functional impairment, panic disorder, or OCD — carries its own risks when left untreated that can exceed the risks of appropriately managed medication. The decision to stop medication should never be assumed to be the risk-free option, because it is not.

What the Evidence Actually Shows About Common Medications

Many psychiatric medications, including a number of SSRIs, have been studied during pregnancy and have extensive real-world data. The picture is nuanced and medication-specific.

SSRIs as a class have the most extensive pregnancy safety data of any psychiatric medication class. For most SSRIs, the available evidence does not suggest a significantly elevated risk of major congenital malformations. There are specific concerns that have been studied — including a possible small increased risk of persistent pulmonary hypertension of the newborn with SSRI use in the second half of pregnancy (some, but not all, studies have found this), and neonatal adaptation syndrome with exposure close to birth — that deserve consideration in the timing and management of medication near the end of pregnancy. The ACOG provides guidance on medication management during pregnancy that reflects the current evidence base and recognizes that treatment of perinatal psychiatric illness is a legitimate and often necessary clinical priority.

The Decision Should Be Individualized

There is no single right answer to the question of psychiatric medication in pregnancy. The relevant considerations include the severity and history of the psychiatric condition, the specific medication and dose, the gestational timing, the person’s prior response to treatment, and the risks of discontinuation versus continuation.

All of these factors need to be on the table in a genuine clinical conversation — one that is honest about uncertainty where uncertainty exists, that presents the evidence accurately without minimizing or catastrophizing, and that centers the person’s own informed judgment. Learning about our approach to women’s psychiatric health and understanding how psychiatric medication works are useful starting points for that conversation.

Please Do Not Stop Medication Without Talking to a Provider First

If you are pregnant or planning a pregnancy and are taking psychiatric medication, please do not stop without first speaking with your prescriber. Abrupt discontinuation of psychiatric medications carries its own risks — both withdrawal effects and the rapid return of symptoms — that can be more destabilizing than a planned, monitored taper or continuation.

A comprehensive psychiatric evaluation during the perinatal period — whether you are pregnant, planning to become pregnant, or recently postpartum — provides the individualized assessment that this decision requires.

Frequently Asked Questions

Is it safe to take antidepressants during pregnancy?

The answer is medication-specific, dose-specific, and individual. SSRIs have the most extensive pregnancy safety data of any psychiatric medication class, and many people continue them through pregnancy with medical guidance. The decision requires weighing the risks of medication against the risks of untreated illness in your specific situation — a determination that requires a clinical conversation, not a general recommendation.

What happens if I stop antidepressants suddenly during pregnancy?

Abrupt discontinuation of antidepressants can produce discontinuation syndrome — flu-like symptoms, dizziness, irritability, sleep disruption — and the rapid return of the underlying psychiatric symptoms. This should be discussed with your prescriber before any changes are made. A planned, monitored approach to any medication changes is significantly safer than abrupt cessation.

Are there psychiatric medications that are definitely unsafe during pregnancy?

Some medications have clearer contraindications during pregnancy than others. Valproate (Depakote) carries significant risks for neural tube defects and cognitive development and is generally avoided. Lithium requires monitoring and consideration of risk-benefit. The specific risks vary significantly by medication, dose, and gestational timing — making individual clinical evaluation essential.

What mental health conditions most commonly require medication during pregnancy?

The conditions most commonly requiring careful medication decisions during pregnancy include major depressive disorder, bipolar disorder, generalized anxiety disorder, OCD, PTSD, and schizophrenia spectrum conditions. The decision is not condition-specific but individual — based on the severity, history, and response to treatment of the specific person.

If you are pregnant or planning a pregnancy and have questions about psychiatric medication — or if you have been managing a mental health condition and are wondering how to navigate this — these are important questions that deserve individualized clinical attention.